VRG Therapeutics Announces Monthly Dosing for Its Lead Program Targeting Kv1.3 for the Treatment of Atopic Dermatitis and Other Chronic Inflammatory Diseases
CREATe-1
Kv1.3
November 6, 2023
By VRG Therapeutics
INNLIFES interview - VRG Therapeutics is the most innovative proposal of MIT4LS 2023
Kv1.3
November 2, 2023
By VRG Therapeutics
Meet in Italy for Life Sciences - Awards
Conference
October 20, 2023
By VRG Therapeutics
BIO-Europe 2023 Startup Spotlight
Conference
October 11, 2023
By VRG Therapeutics
Bio Europe 2023 - Startup Spotlight
Conference
September 25, 2023
By VRG Therapeutics
Meet in Italy for Life Sciences - Startup Breeding 2023
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.